Polaris Capital Management said the following ... switching patients to Skyrizi or Rinvoq rather than Humira biosimilars.” Bristol-Myers Squibb Company (NYSE:BMY) is a biopharmaceutical company ...

Existing backers also bought in, including Bristol Myers Squibb, Eli Lilly, Pfizer Ventures, Novartis Venture Fund, Leaps by Bayer, Alexandria Venture Investments, Polaris Partners, and Vida Ventures.

This was the stock's second consecutive day of losses.

William Blair upped their Q2 2025 earnings estimates for Bristol-Myers Squibb in a note issued to investors on Tuesday, March ...

Bristol Myers Squibb Co. closed 6.82% below its 52-week high of $63.33, which the company reached on March 11th.

Bristol Myers Squibb to acquire 2seventy Bio for $5.00 per share in a $286 million all-cash deal, an 88% premium to its last ...

Bullish option flow detected in Bristol Myers ( BMY) Squibb with 17,811 calls trading, 1.1x expected, and implied vol increasing over 2 points to 28.33%. May-25 60 calls and 3/14 weekly 63 calls are ...

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other Friday’s ...

The most recent trading session ended with Bristol Myers Squibb (BMY) standing at $60.28, reflecting a +0.79% shift from the previouse trading day's closing. The stock outpaced the S&P 500's daily ...

March 11 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab will acquire 2seventy bio (TSVT.O), opens new tab for about $286 million in cash, sending the cancer cell therapy maker's shares up ...

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the other dividend stocks. Dividend stocks have taken a backseat in the market as ...

Bristol-Myers Squibb was founded in 1858 and has grown to be one of today's leading global pharmaceutical companies. For over 150 years, Bristol-Myers Squibb (BMS) has been committed to "discover ...